Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?: https://g.foolcdn.com/editorial/images/769667/a-person-sitting-at-their-home-office-desk-using-a-laptop-computer-getty.jpg
2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

Investors looking for stocks that can deliver heaps of passive income might want to turn their heads toward the healthcare sector. Right now, there are a couple of beaten-down stocks offering

Will Pfizer Be a Trillion-Dollar Stock by 2035?: https://g.foolcdn.com/editorial/images/769917/scientists-in-a-lab-monitor-microscope.jpg
Will Pfizer Be a Trillion-Dollar Stock by 2035?

Some investors look at Pfizer (NYSE: PFE) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue

3 Stocks I'm Adding to My Retirement Account in March: https://g.foolcdn.com/editorial/images/769607/gettyimages-1384411573.jpg
3 Stocks I'm Adding to My Retirement Account in March

Whenever I decide on a stock, my mindset is that I'll stay invested in it for nothing short of a decade. Ideally, you're investing in great companies you feel comfortable holding on to until

Could Viking Therapeutics Become the Next Eli Lilly?: https://g.foolcdn.com/editorial/images/770100/gettyimages-1220595235.jpg
Could Viking Therapeutics Become the Next Eli Lilly?

Eli Lilly (NYSE: LLY) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.

Doctors have been prescribing Mounjaro and the

Want Decades of Passive Income? 2 Stocks to Buy Now.: https://g.foolcdn.com/editorial/images/769462/physician-shaking-patients-hand.jpg
Want Decades of Passive Income? 2 Stocks to Buy Now.

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And

EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Viking Therapeutics Stock Has 55% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/770094/person-in-a-lab-looking-through-a-microscope.jpg
Viking Therapeutics Stock Has 55% Upside, According to 1 Wall Street Analyst

There are potential share price gains, and then there are potential share price gains. In the view of one analyst, Viking Therapeutics (NASDAQ: VKTX) currently stands in front of the latter variety.

Is Pfizer the Best Dividend Stock for You?: https://g.foolcdn.com/editorial/images/769786/a-couple-reviewing-a-document-at-home.jpg
Is Pfizer the Best Dividend Stock for You?

If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As

Is Amgen Stock a Buy Now?: https://g.foolcdn.com/editorial/images/769464/physician-giving-medicine-to-elderly-patient.jpg
Is Amgen Stock a Buy Now?

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

Should You Buy AT&T While It's Below $20?: https://g.foolcdn.com/editorial/images/769302/small-retail-store-with-_att-logo_att.jpg
Should You Buy AT&T While It's Below $20?

Telecom giant AT&T (NYSE: T) has seemingly hung around the $20 mark for years. Today, shares are trading hands at $17. The stock has underperformed the S&P 500 due to a bloated balance sheet and

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration: https://mms.businesswire.com/media/20240319984906/en/2072888/5/Graph_1_ENG.jpg
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319984906/en/



Graph 1: Evolution of Best-Corrected Visual Acuity


Warning: This Skyrocketing Stock Has a Hidden Risk: https://g.foolcdn.com/editorial/images/769495/chart-reflected-on-investor-glasses.jpg
Warning: This Skyrocketing Stock Has a Hidden Risk

Viking Therapeutics' (NASDAQ: VKTX) stock is up an eye-popping 860% over the last three years, with the lion's share of those gains occurring in the last few months. The biotech's pursuit of

EQS-News: Newron presents 2023 financial results and provides 2024 outlook: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move: https://g.foolcdn.com/editorial/images/769387/light-bulb-drawings-with-a-person-thinking.jpg
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move

Pfizer (NYSE: PFE) has seen its better days. Shares of the big drugmaker have plunged more than 50% from the highs set in late 2021. The pharma stock is down more than 30% over the last 12 months

2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now: https://g.foolcdn.com/editorial/images/769170/pharmacist-talking-to-patient.jpg
2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

There are many ways to spend $1,000. One could buy a brand-new flat-screen television, play the lottery, or keep it in a savings account. For people trying to increase their capital, though

Where Will Viking Therapeutics Be in 5 Years?: https://g.foolcdn.com/editorial/images/769164/investor-stands-in-kitchen-considering-laptop.jpg
Where Will Viking Therapeutics Be in 5 Years?

Today, Viking Therapeutics (NASDAQ: VKTX) has no products, no revenue, and happily, almost no debt. By early 2029, the odds are good that none of those factoids will still be true if the biotech is

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation: https://g.foolcdn.com/editorial/images/769331/young-woman-smiling-hands-behind-head.jpg
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation

Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case.

Three Motley Fool contributors have

2 Top Dividend Stocks to Buy Hand Over Fist: https://g.foolcdn.com/editorial/images/769084/physician-giving-medicine-to-elderly-patient.jpg
2 Top Dividend Stocks to Buy Hand Over Fist

Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a

Will Viking Therapeutics Get Acquired?: https://g.foolcdn.com/editorial/images/768791/people-agreeing-on-a-deal.jpg
Will Viking Therapeutics Get Acquired?

Viking Therapeutics (NASDAQ: VKTX) has been one of the hottest healthcare stocks of 2024. Shares of the company have risen by 285% thus far, and that's even factoring in a recent pullback in price

The Smartest Dividend Stocks to Buy With $400 Right Now: https://g.foolcdn.com/editorial/images/769421/gettycelebratingwomanphone.jpg
The Smartest Dividend Stocks to Buy With $400 Right Now

This week's inflation data came in a little bit hot, but it doesn't mean that rates on traditional fixed income investments will stay high for much longer. When the climate starts to get kinder --

2 Stocks That Have More Than Tripled This Year: Are They Buys?: https://g.foolcdn.com/editorial/images/768669/doctor-holding-elderly-patients-hand.jpg
2 Stocks That Have More Than Tripled This Year: Are They Buys?

Finding stocks that can triple in two years is hard enough. Finding those that can do so in a mere two months is that much more impressive. That's precisely what Viking Therapeutics (NASDAQ: VKTX)

Is Pfizer Stock a Millionaire Maker?: https://g.foolcdn.com/editorial/images/768804/a-team-of-scientists-reviewing-results-in-a-lab.jpg
Is Pfizer Stock a Millionaire Maker?

The stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant are down 28% over the past 12 months as

Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?: https://g.foolcdn.com/editorial/images/769056/big-fish-eating-little-fish.jpg
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Why Coherus Biosciences Stock Tumbled on Thursday: https://g.foolcdn.com/editorial/images/769378/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Coherus Biosciences Stock Tumbled on Thursday

The final set of results for Coherus Biosciences' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock